

PBAC recommended listings/amendments not yet listed

Please note – the information below is accurate as at 3 April 2019

PBAC Meeting November 2018		
MEDICINE	INDICATION	STATUS
ENCORAFENIB and BINIMETINIB Encorafenib: capsule 50 mg capsule 75 mg Binimetinib: tablet 15 mg BRAFTOVI® and MEKTOVI® Pierre Fabre Australia Pty Ltd	Melanoma	No price offer received from sponsor
FERRIC CARBOXYMALTOSE Injection 1,000 mg (iron) in 20 mL Ferinject® Vifor Pharma Pty Limited <i>new form</i>	Iron deficiency anaemia	Sponsor currently has no stock
GLYCOMACROPEPTIDE FORMULA WITH DOCOSAHEXAENOIC ACID WITH LOW PHENYLALANINE Sachets containing oral powder 33.3 g, 16 (PKU GMPro) PKU GMPro Nutricia Australia Pty Limited	Phenylketonuria (PKU)	Sponsor currently has no stock
INSULIN ASPART Injections (human analogue), pre filled pen, 100 units per mL, 3mL Injections (human analogue), vial, 100 units per mL, 10 mL Injections (human analogue), cartridges, 100 units per mL, 3 mL Fiasp® Novo Nordisk Pharmaceuticals Pty Ltd	Diabetes Mellitus	Sponsor currently has no stock
ISOTRETINOIN Capsule 5 mg Oratane® Oraderm Pharmaceuticals Pty Ltd	Severe cystic acne	Sponsor currently has no stock
PEGFILGRASTIM Injection 6 mg in 0.6 mL single use pre-filled syringe Fulphila® Alphapharm Pty Ltd	Chemotherapy-induced neutropenia	No price offer received from sponsor
PEMBROLIZUMAB Solution concentrate for I.V. infusion 100 mg in 4 mL Keytruda® Merck Sharp & Dohme (Australia) Pty Ltd	Melanoma	Negotiations with sponsor are continuing
SARILUMAB Injection 200 mg in 1.14 mL pre-filled syringe Injection 150 mg in 1.14 mL pre-filled syringe Kevzara® Sanofi-Aventis Australia Pty Ltd	Rheumatoid arthritis	Sponsor advised not proceeding
TESTOSTERONE Transdermal gel (pump pack) 23 mg per 1.15 g dose, 56 doses Testavan® Ferring Pharmaceuticals Pty Ltd	Androgen deficiency; Micropenis; Pubertal induction; Constitutional delay of growth or puberty	Sponsor currently has no stock

PBAC Meeting July 2018		
MEDICINE	INDICATION	STATUS
BUDESONIDE Capsule (modified release) 3 mg Entocort® Emerge Health Pty Ltd	Mild to moderate Crohn disease	Resubmission to PBAC

<b>PBAC Meeting July 2018</b>		
<b>MEDICINE</b>	<b>INDICATION</b>	<b>STATUS</b>
CARMELLOSE HYPROMELLOSE Eye drops containing carmellose sodium 5 mg per mL, 10 mL Eye drops containing hypromellose 3 mg per mL, 10 mL Evolve® carmellose Evolve® hypromellose Contact Lens Centre Australia	Severe dry eye syndrome	Sponsor advised not proceeding
INSULIN GLARGINE Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5 Semglee® Alphapharm Pty Ltd	Unrestricted (indicated for diabetes mellitus)	Sponsor advised not proceeding

<b>PBAC meeting March 2018</b>		
<b>ITEM</b>	<b>INDICATION</b>	<b>STATUS</b>
RAMUCIRUMAB (Cyramza®) Injection concentrate for I.V. infusion 100 mg in 10 mL Injection concentrate for I.V. infusion 500 mg in 50 mL Eli Lilly Australia Pty Ltd	Advanced gastric or gastro-oesophageal junction adenocarcinomas	Resubmission to PBAC
RANOLAZINE (Ranexa®) Tablet (modified release) 375 mg Tablet (modified release) 500 mg Tablet (modified release) 750 mg A. Menarini Australia Pty Ltd	Stable angina pectoris	No price offer received from sponsor

<b>PBAC meeting November 2017</b>		
<b>ITEM</b>	<b>INDICATION</b>	<b>STATUS</b>
RADIUM (223Ra) Injection containing radium (223Ra) dichloride 6.6 MBq in 6 mL vial Xofigo® Bayer Australia Ltd	Metastatic castrate resistant prostate cancer (mCRPC)	Resubmission to PBAC
SEVELAMER Powder for oral liquid 2.4 g (as carbonate) Renvela® Sanofi-Aventis Australia Pty Ltd	Hyperphosphataemia in patients with chronic kidney disease	No price offer received from sponsor

<b>PBAC meeting March 2017</b>		
<b>ITEM</b>	<b>INDICATION</b>	<b>STATUS</b>
TENOFOVIR ALAFENAMIDE Tablet 25 mg Vemlidy® Gilead Sciences Pty Ltd	Chronic hepatitis B	No price offer consistent with PBAC advice received from sponsor

<b>PBAC meeting July 2016</b>		
<b>ITEM</b>	<b>INDICATION</b>	<b>STATUS</b>
PNEUMOCOCCAL CONJUGATE VACCINE 13-Valent Adsorbed Pre-Filled Syringe, 0.5 mL, Prevenar 13® Pfizer Australia Pty Ltd	Prevention of pneumococcal disease – Aboriginal and Torres Strait Islander adults 50+ and non-Indigenous adults 65+	Awaiting the outcomes of the PBAC's review of the 23 valent pneumococcal vaccine (Pneumovax 23, Seqirus) at the March 2019 PBAC meeting.